InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-02 | Skaff Michael C | 10% Owner | Purchase | 1.35M | $1.34 | $1.81M | 1.35M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenue | $11.0M+53.1% | $7.2M-5.0% | $7.5M-1.5% | $7.6M-26.3% | $10.4M |
| Cost of sales (exclusive of depreciation and amortization shown separately below) | $6.9M+14.8% | $6.0M+8.7% | $5.5M-7.9% | $6.0M+40.3% | $4.3M |
| Gross profit | $10.5M+16.9% | $9.0M+9.0% | $8.3M-17.4% | $10.0M-20.5% | $12.6M |
| General and administrative | $27.7M+55.1% | $17.9M-20.5% | $22.5M-22.6% | $29.0M+12.6% | $25.8M |
| Sales and marketing | $1.4M-19.1% | $1.7M-29.8% | $2.5M-53.8% | $5.3M-3.8% | $5.6M |
| Depreciation and amortization | $1.3M+125.3% | $581K-6.4% | $621K-7.2% | $669K-8.7% | $733K |
| Total operating expenses | $30.4M+50.7% | $20.2M-21.0% | $25.6M-27.1% | $35.0M+6.3% | $33.0M |
| Operating loss | -$19.9M-78.1% | -$11.2M+35.4% | -$17.3M+30.9% | -$25.0M-22.8% | -$20.4M |
| Other expense | -$1.5M-1246.4% | -$110K+48.1% | -$212K-11.6% | -$190K-2011.1% | -$9K |
| Other income | $145K+0.0% | $145K-1.4% | $147K+65.2% | $89K-23.9% | $117K |
| Loss before income taxes | -$21.2M-90.6% | -$11.1M+18.0% | -$13.6M+43.0% | -$23.8M-17.5% | -$20.3M |
| Net loss | -$21.2M-90.6% | -$11.1M+18.0% | -$13.6M+43.0% | -$23.8M-17.5% | -$20.3M |
| Net loss attributable to non-controlling interest | -$60K | — | — | — | — |
| Net loss attributable to stockholders | -$21.2M-90.1% | -$11.1M+18.0% | -$13.6M+43.0% | -$23.8M-17.5% | -$20.3M |
| Net loss per share (basic) | -$2K+6.8% | -$2K+80.1% | -$11K+57.0% | -$26K-2597.9% | -$960 |
| Net loss per share (diluted) | -$2K+6.8% | -$2K+80.1% | -$11K+57.0% | -$26K | — |
| Weighted average number of shares of Common Stock outstanding (basic) | $10.27B+104.7% | $5.02B+311.7% | $1.22B+32.5% | $920.6M-95.7% | $21.23B |
| Weighted average number of shares of Common Stock outstanding (diluted) | $10.27B+104.7% | $5.02B+311.7% | $1.22B+32.5% | $920.6M | — |
| Product [Member] | |||||
| Service [Member] | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates